Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Carter Dufrane"'
Autor:
Julie Lemieux, Michael Gnant, Amylou C. Dueck, Georg Pfeiler, Meritxell Bellet-Ezquerra, Antonio C. Wolff, Magdalena Schwarz, Marcus Vetter, Angela DeMichele, Kathy D. Miller, Kathy Puyana Theall, Miguel Gil-Gil, Hannes Fohler, Patrick G. Morris, Maria Koehler, Stacy L. Moulder, Matthew Bidwell Goetz, Manuel Ruiz-Borrego, Arlene Chan, Aleix Prat, G. Rubovszky, Silvia Antolin Novoa, Otto Metzger Filho, Miguel Martín, Debora Fumagalli, Erica L. Mayer, D. Lu, Fernando Henao, Christian Fesl, Eric P. Winer, Florian Fitzal, Alistair Ring, Tiffany A. Traina, Carter Dufrane, Harold J. Burstein, Sibylle Loibl, Nicholas Zdenkowski, Daniel Egle, Hope S. Rugo, Cynthia Huang Bartlett, Daniel G. Anderson, Eleftherios P. Mamounas, Alan P. Lyss, Zbigniew Nowecki
Publikováno v:
The Lancet. Oncology
Summary Background Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial aimed to investigate whether the addition of 2 years of palbociclib t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6787d365738e1b450b902b6d51989545
https://doi.org/10.1016/s1470-2045(20)30642-2
https://doi.org/10.1016/s1470-2045(20)30642-2
Autor:
Catherine Lai, G. Viale, A Nguyen Duc, Heather L. McArthur, M.J. Piccart, M Ignatiadis, R. D. Gelber, Noam Pondé, Fergus Daly, Otto Metzger, Theodora Goulioti, E. de Azambuja, J-L Martinez, EP Winer, Andrew Bailey, Carter Dufrane, M Maetens, A. Bouhlel, V. Balta, V Van Dooren
Publikováno v:
Cancer Research. 79:OT3-05
Background: Triple negative breast cancer (TNBC) is a subtype with a high risk of relapse in the early disease setting. Because TNBC does not currently have specific targeted agents approved for use in the early setting it is treated primarily with c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd34cedbad9b04a2c6fee6288b13f25a
https://doi.org/10.1158/1538-7445.sabcs18-ot3-05-02
https://doi.org/10.1158/1538-7445.sabcs18-ot3-05-02
Autor:
Katja Schulze, Junheng Gao, Carter Dufrane, Xiaofei Wang, David Kozono, Helen J. Ross, Everett E. Vokes, Ilze Bara, James J. Urbanic, Terence M. Williams, Tom Stinchcombe, Jane Michelle Brockman
Publikováno v:
Journal of Clinical Oncology. 39:8513-8513
8513 Background: A minority of the approximately 40,000 US patients diagnosed annually with stage III NSCLC can be cured by concurrent CRT. Standard adjuvant immune checkpoint inhibitors (ICI) improve outcome for those patients who complete CRT with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9e09b57e655ed633a2a17dca8903d18
https://doi.org/10.1200/jco.2021.39.15_suppl.8513
https://doi.org/10.1200/jco.2021.39.15_suppl.8513
Autor:
Michail Ignatiadis, Shigehira Saji, Sebastien Guillaume, Carter Dufrane, Heather L. McArthur, Catherine Lai, Vanessa Honvault, Debora Fumagalli, Richard D. Gelber, Martine Piccart-Gebhart, Giuseppe Viale, Rosa Altarcheh Xifro, Andrew Bailey, Aicha Seiller, Sarra El-Abed, Mariana Brandão, Teresa Barata, Otto Metzger, Dominique Agbor-Tarh, Eric P. Winer
Publikováno v:
Journal of Clinical Oncology. 39:TPS597-TPS597
TPS597 Background: Early stage triple negative breast cancer (TNBC) is associated with a high risk of distant relapse. Because TNBC does not currently have specific targeted agents approved for use in the early setting, it is treated primarily with c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e55c2c6a3172d2565ea57f153386ece1
https://doi.org/10.1200/jco.2021.39.15_suppl.tps597
https://doi.org/10.1200/jco.2021.39.15_suppl.tps597
Autor:
Xiaofei Wang, Katja Schulze, Tom Stinchcombe, JaneMichelle Michelle Brockman, Helen J. Ross, Everett E. Vokes, James J. Urbanic, M. Gandhi, Junheng Gao, Carter Dufrane, Terence M. Williams, David Kozono, Ilze Bara
Publikováno v:
Journal of Clinical Oncology. 38:9045-9045
9045 Background: A minority of the > 40,000 patients (pts) diagnosed with stage III NSCLC annually in the US are cured by CRT, more recently followed by adjuvant immune checkpoint inhibitors (ICI). PD-L1 blockade with CRT may attenuate tumor-related
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83fbae4e2baf0c48c12c3cce6ed9efb5
https://doi.org/10.1200/jco.2020.38.15_suppl.9045
https://doi.org/10.1200/jco.2020.38.15_suppl.9045
Autor:
M Maetens, C. Lai, M.J. Piccart, Heather L. McArthur, A. Bouhlel, Fergus Daly, Maria Alice Franzoi, V. Balta, E. de Azambuja, R. D. Gelber, Andrew Bailey, EP Winer, G. Viale, D.A. Nguyen, M Ignatiadis, José Luis Martínez, Theodora Goulioti, B. André, Carter Dufrane, Otto Metzger
Publikováno v:
Annals of Oncology. 30:v97
Background Early stage triple negative breast cancer (TNBC) is associated with a high risk of distant relapse. Because TNBC does not currently have specific targeted agents approved for use in the early setting it is treated primarily with chemothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b798543955a70ebe19bd779465ea38f
https://doi.org/10.1093/annonc/mdz240.112
https://doi.org/10.1093/annonc/mdz240.112
Autor:
Richard D. Gelber, Debora Fumagalli, Martine Piccart, Anh Nguyen Duc, Giuseppe Viale, Fergus Daly, Vanessa Honvault, Otto Metzger, Andrew Bailey, Heather L. McArthur, Eric S. Winer, Christie Freeman, Sebastian Guillaume, Valeria Karusinova, Catherine Lai, Jorge Luis Martinez, Mariana Brandão, Carter Dufrane, Aicha Bouhlel, Michail Ignatiadis
Publikováno v:
Journal of Clinical Oncology. 37:TPS598-TPS598
TPS598 Background: Early stage triple negative breast cancer (TNBC) is associated with a high risk of distant relapse. Because TNBC does not currently have specific targeted agents approved for use in the early setting it is treated primarily with ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::410f0cc9f3de5d6daf13e74942b22b18
https://doi.org/10.1200/jco.2019.37.15_suppl.tps598
https://doi.org/10.1200/jco.2019.37.15_suppl.tps598